Efficacy and Safety of a Topical Botanical Extract Formulation for Skin Aging
Efficacy Evaluation of a Botanical Extract in Simple Skincare Formulations for Anti-Ageing: A Single Center, Double-Blinded, Placebo-Controlled, Randomized, Split-Face Study
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This is a single-center, double-blinded, placebo-controlled, split-face, prospective clinical study designed to evaluate the anti-ageing efficacy and safety of a botanical extract. 66 subjects with dry skin on both sides of their faces were recruited. A split-face design is utilized in this study. Test products are applied topically twice daily for 56 days.
The primary objective is to assess the skin anti-ageing efficacy (instrumental evaluations including skin tone & wrinkles, and clinical gradings on signs of ageing) of the active botanical extract compared to a placebo. The secondary objective is to investigate potential mechanisms via untargeted proteomics.
Instrumental evaluations and clinical scorings are performed at Baseline, Day 28, and Day 56. Non-invasive D-Squame tape-stripping samplings for proteomics analysis are collected at Baseline and Day 56.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Shanghai, Chine
- L'OREAL R&I China
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Chinese female subjects aged 35 to 60 years (inclusive) in good general health based on subjective self-report and investigator assessment.
- Fitzpatrick skin type II, III, or IV.
- Self-reported dry skin type.
- Meets specified skin criteria assessed by investigator: Crow's feet wrinkle grade between 3 and 5 (inclusive), with priority given to subjects with a side-to-side difference ≤ 0.5 in grade.
- Facial trans-epidermal water loss (TEWL) ≥ 6 g/m²·h as measured by Vapometer.
- Facial stratum corneum hydration level between 20 and 45 (inclusive) as measured by Corneometer.
- Willing to avoid excessive sun exposure throughout the study period.
- Females of childbearing potential (FCBP) must agree to use highly effective contraception methods or remain abstinent from 1 month prior to study start through study completion; or postmenopausal females.
- FCBP must have a negative urine pregnancy test at screening.
- Willing to undergo tape-stripping procedures for stratum corneum sampling.
- No other dermatological conditions deemed unsuitable for participation (e.g., facial tattoos, scars).
- Willing to sign Informed Consent Form (ICF) and Image Authorization Form.
- Able and willing to comply with all study procedures and visit schedules.
Exclusion Criteria:
- Current pregnancy, breastfeeding, or planning to become pregnant.
- Current smokers or history of smoking within the last 6 months (including e-cigarettes/nicotine products).
- History of facial cosmetic procedures (fillers, lasers, implants, Botox, etc.).
- Active systemic or localized skin diseases (acne, eczema, psoriasis, atopic dermatitis).
- Known allergies to cosmetics, personal care products, or their ingredients.
- Excessive UV exposure or frequent sauna/water sports usage.
- Use of antihistamines, antibiotics, corticosteroids, or NSAIDs within relevant washout periods.
- Participation in any other clinical trial within the past 30 days.
- Planned surgical or invasive procedures during the study period.
- Individuals deprived of liberty by judicial or administrative order.
- Subjects who cannot be reached by telephone in case of an emergency.
- Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Experimental: 0.05% Active Formulation
Formulation with 0.05% botanic extract
|
Topical skincare formulation containing Botanical Extract (Concentration 1, 0.05%).
Applied topically twice daily for 56 days
|
|
Comparateur placebo: Placebo: Vehicle control 1
Applying the placebo formula without active ingredient
|
Topical skincare formulation base (identical to Active Formulation 1 but without the active botanical extract).
Applied topically twice daily for 56 days.
|
|
Expérimental: Experimental: 0.14% Active Formulation
Formulation with 0.14% botanic extract
|
Topical skincare formulation containing Botanical Extract (Concentration 2, 0.14%).
Applied topically twice daily for 56 days.
|
|
Comparateur placebo: Placebo: Vehicle Control 2
Applying the placebo formula without active ingredient
|
Topical skincare formulation base (identical to Active Formulation 2 but without the active botanical extract).
Applied topically twice daily for 56 days.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Instrumental Evaluation of Skin Tone, Elasticity, and Wrinkles
Délai: Baseline, Day 28, Day 56
|
Evaluation of skin color/tone using Colorimeter (CL400), skin elasticity using Cutometer (MPA 580), and crow's feet wrinkles using PRIMOS CR (Canfield Scientific)
|
Baseline, Day 28, Day 56
|
|
Clinical Scoring of Facial Ageing Signs
Délai: Baseline, Day 28, and Day 56
|
Dermatological grading of crow's feet wrinkles, forehead wrinkles, fine lines on forehead, inter-ocular wrinkles, underneath eye wrinkles, visual smoothness, tactile smoothness, firmness, and skin elasticity using standard clinical visual/tactile grading scales. crow's feet(0-6, the higher the worse), forehead wrinkles(0-8, the higher the worse), fine lines on the forehead(0-7,the higher the worse), inter-ocular wrinkles(0-7, the higher the worse), underneath eye wrinkles(0-9, the higher the worse),smoothness(Visual)(0-9,the higher the worse), smoothness(tactile)(0-9,the higher the worse), firmness(0-9,the higher the worse), skin elasticity(0-9,the higher the worse) |
Baseline, Day 28, and Day 56
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Trans-epidermal water loss(TEWL)
Délai: Baseline, Day 28, Day 56
|
trans-epidermal water loss using Vapometer (Vapometer, Delfin)
|
Baseline, Day 28, Day 56
|
|
Skin Hydration Index
Délai: Baseline, Day 28, Day 56
|
Hydration Index using Corneometer(Corneometer CM 825, Courage-Khazaka)
|
Baseline, Day 28, Day 56
|
|
Epidermal Proteomic Profile Changes
Délai: Baseline and Day 56
|
Characterization and untargeted proteomics analysis of epidermal biomarkers obtained via non-invasive tape-stripping (D-Squame) sampling
|
Baseline and Day 56
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- ACR_EV_25-11289_01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .